Guide to Long Acting HIV Prevention Options and Their Benefits

Lenacapavir is an antiretroviral medicine that works by interfering with the HIV capsid, which helps protect and transport the virus's genetic material. For HIV prevention, it is an important option for eligible people who may benefit from long acting pre exposure prophylaxis, commonly called PrEP. Unlike daily oral prevention medicines, injectable lenacapavir can provide protection over an extended period when administered according to the recommended schedule. Its use requires appropriate HIV testing, clinical assessment, and follow up with a healthcare professional.

Understanding Lenacapavir Dosing for HIV Prevention

Lenacapavir for HIV prevention is administered according to a specific initiation schedule followed by maintenance injections. The exact regimen depends on the approved product instructions and applicable clinical guidance. People should follow their healthcare professional's directions rather than adjusting doses independently.

• Initial dosing: The starting phase prepares the medicine to provide the intended level of protection. Depending on the prescribed regimen, this phase can involve oral doses and injections on specified days.

• Maintenance injections: After initiation, injections are administered at regular intervals, generally every six months for the approved HIV prevention regimen.

• HIV testing: Testing is necessary before starting PrEP and at recommended follow up visits to identify HIV infection promptly.

• Missed appointments: People who cannot attend an injection appointment should contact their healthcare professional as soon as possible to discuss the appropriate next steps and maintain prevention coverage.

Lenacapavir should not be started or continued without following the prescribed medical schedule. A healthcare professional can explain the dosing calendar, evaluate other medicines for potential interactions, and advise on the steps required if an injection is delayed.

Lenacapavir Effectiveness and Safety Considerations

Clinical trials have demonstrated high effectiveness for lenacapavir as HIV PrEP. In the PURPOSE 1 and PURPOSE 2 trials, effectiveness was estimated at 100% among female participants and 96% among a primarily male participant population compared with estimated HIV incidence without PrEP over approximately 52 weeks. These results reflect the study populations and conditions and do not guarantee complete protection for every individual.

MMWR

+1

Important considerations include:

• Possible side effects: Injection site pain, swelling, redness, or small nodules may occur. Most reported reactions were mild to moderate.

• HIV status confirmation: HIV infection must be excluded before starting PrEP. Regular testing is essential because using lenacapavir in someone with undiagnosed HIV may contribute to drug resistance.

• Drug interactions: Certain medicines can affect lenacapavir levels or interact with it. A healthcare professional should review prescription medicines, over the counter products, and supplements.

• Ongoing protection: Lenacapavir does not prevent other sexually transmitted infections. Additional prevention measures, including condoms where appropriate, remain important.

• Availability and eligibility: Approval, access, and prescribing recommendations can differ by country. A qualified healthcare professional can explain local guidance and whether this medicine is suitable.

Lenacapavir is an important development in HIV prevention because its twice yearly injection schedule may help people who find daily medication difficult to maintain. However, its benefits depend on appropriate medical assessment, timely dosing, HIV testing, and follow up. Anyone considering this option should discuss their prevention needs and medical history with a healthcare professional. This article is intended for general educational purposes only and does not provide medical advice or promote a product or service.